[ad_1] Jazz Pharmaceuticals (NASDAQ: JAZZ) 2.9% falls in after-hours trading after reporting results of a late-stage trial of liposome Vyxeos for injections in two kinds of blood cancer. The study 309 patients …
Read More »Jazz reports late-stage trial for Vyxeos in blood cancer meets the goal – Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ)
